Study finds long-acting cabotegravir and rilpivirine maintains HIV viral suppression
Research presented at IDWeek shows that long-acting injectable antiretroviral therapy combining cabotegravir and rilpivirine consistently maintains virologic suppression in adults with HIV who were previously virologically suppressed. The real-world study addresses questions about the effectiveness of switching from oral to injectable ART.